

Pharmacy BULLETIN BOARD

Retail Issue ■ Monday August 11, 2014

Attention: BC Pharmacists

Boehringer Ingelheim and Eli Lilly are pleased to inform you that along with **Trajenta[®]**, **Jentadueto[™]** (linagliptin/metformin HCl) is now also covered by the BC PharmaCare program, effective August 5, 2014.

For complete listing criteria, please refer to the formulary listing at <http://www.health.gov.bc.ca/pharmacare/sa/criteria/restricted/linagliptin.html>

To order Trajenta[®] or Jentadueto[™] please contact your preferred wholesaler or Boehringer Ingelheim Customer Care at 1-800-263-2425.

Trajenta [®]		
Dose – Linagliptin	DIN	UPC
5 mg, TABS 30S	02370921	058341020195
5 mg, TABS 90S	02370921	058341020201

Jentadueto [™]			
Dose		DIN	UPC
Linagliptin	Metformin HCl		
2.5 mg	500 mg	02403250	058341020317
2.5 mg	850 mg	02403269	058341020324
2.5 mg	1000 mg	02403277	058341020331

To learn more about Trajenta[®] or Jentadueto[™], contact your Boehringer Ingelheim/Eli Lilly Alliance representative, or Medical Information at 1-800-263-5103 (x84633).

Trajenta[®] is a registered trademark used under license by Boehringer Ingelheim (Canada) Ltd.
Jentadueto[™] is a trademark used under license by Boehringer Ingelheim (Canada) Ltd.




FROM THE NEWSWIRE

VANCOUVER: The Canadian Foundation for Healthcare Improvement announced its support for 22 teams from healthcare organizations across Canada to partner with patients and families on quality improvement initiatives. Teams from six provinces and one territory will harness the tremendous potential of patient and family engagement to improve the quality and efficiency of health services.

Odan Labs wishes to remind you that **Adasept[®] Skin Cleanser** and **Tardan[®] Shampoo** are ideal therapeutic replacements for the discontinued products Tersaseptic[†] and Polytar[†].

Product	Comparative	Sizes	Odan Code	Kohl & Frisch Code	McKesson Code	McMahon Code
Adasept [®] Skin Cleanser 00266507	Tersaseptic [†]	250 mL	020J	46307	115204	26623301
		500 mL	020L	46308	413062	26679101
Tardan [®] Shampoo 00266493	Polytar [†]	250 mL	170J	46311	115428	26723701
		500 mL	170L	46314	333633	

Adasept[®] Antibacterial Cleanser and **Tardan[®]** dandruff shampoo are prescribed by dermatologists and physicians across Canada. Both products are used in hospitals and by patients nationwide.

To order, please contact your preferred wholesaler or contact Odan at 1-800-387-9342 or by e-mail at info@odanlab.com. You can also visit our website at www.odanlab.com.



Adasept[®] and Tardan[®] are registered trademarks of Odan Laboratories Ltd.
† Tersaseptic and Polytar are trademarks of Stiefel, a GSK company

Attention Pharmacy Technicians!

Don't miss the 32nd Annual Pharmacy Technician Conference on October 4th, 2014

Hosted by:



Humber Institute of Technology & Advanced Learning
Lakeshore Campus, 3199 Lake Shore Boulevard West,
Toronto ON, M8V1K8

Join us at this one-day educational conference supporting the important roles of the Pharmacy Technician and learn about *Pushing the Boundaries...*

Informative speakers & sessions, networking opportunities, panel discussions and more!

Visit our website for Conference Program, Speaker and Event details!

www.pharmacy.humber.ca

For more information contact: Arielle Berube, Humber Conference Services
Email: hcs@humber.ca Phone: 416-675-6622 x 77312



Now an Interchangeable Benefit in Ontario!!!

PrTaro-Mometasone Lotion 0.1%

Mometasone Furoate

Taro-Mometasone Lotion 0.1% is now an Interchangeable Benefit on the Ontario Formulary.

- Bioequivalent & Interchangeable with Elocom®¹
- High Quality, Lower Price Alternative
- Available for Immediate Shipping

Form	Strength	DIN	Size	UPC	Wholesaler			
					McKesson	K&F	Procurity	McMahon
Lotion	0.1%	02266385	30 mL	063691063112	901355	105829	250155	10056151
			75 mL	063691063129	901330	105830	250830	10056118

For more information, or to place an order for **Taro-Mometasone Lotion 0.1%**, please contact your Taro Representative, your wholesaler, our Customer Service department at **1-800-268-1975**, or visit our Website at www.taro.ca.

¹ Data on file, Taro Pharmaceuticals Inc.
 ® Elocom is a registered trademark of Schering Canada Inc.
 TARO is a registered trademark of Taro Pharmaceuticals Inc.



Lower Cost Generic Alternative of Imitrex® Injection¹

PrTaro-Sumatriptan

Sumatriptan Succinate Injection 6mg/ 0.5mL

- Generic Version of Imitrex® Injection¹
- High Quality, Lower Price Alternative
- One piece disposable device with no assembly required
- Indicated for the acute treatment of migraine attacks with or without aura

Form	Strength	DIN	Size	UPC	Wholesaler			
					McKesson	K&F	Procurity	McMahon
Subcutaneous Injection	6 mg/ 0.5 mL	02361698	2 x 0.5 mL	063691068056				
					010333	119700	251763	10056869

For further information, or to place an order for **Taro-Sumatriptan Injection**, please contact your Taro Representative, your wholesaler, our Customer Service department at **1-800-268-1975**, or visit our Website at www.taro.ca.

¹Data on file, Taro Pharmaceuticals Inc.
 ®Imitrex is a registered trademark, used under license of GlaxoSmithKline Inc.
 Taro is a registered trademark of Taro Pharmaceuticals Inc.



Now Listed on the Alberta, Saskatchewan, Ontario & New Brunswick Formularies!!!

PrTaro-Carbamazepine

Carbamazepine Tablets 200mg

Taro-Carbamazepine Tablets 200mg are now an Interchangeable Benefit on the Alberta, Saskatchewan, Ontario & New Brunswick Formularies.

- Bioequivalent to Tegretol®¹
- High Quality, Lower Price Alternative

Form	Strength	DIN	Size	UPC	Wholesaler			
					McKesson	K&F	Procurity	McMahon
Tablet	200 mg	02407515	500	063691072671				
					063139	147883	279226	10071281

For more information, or to place an order for **Taro-Carbamazepine 200 mg Tablets**, please contact your Taro Representative, your wholesaler, our Customer Service department at **1-800-268-1975**, or visit our Website at www.taro.ca.

¹ Data on file, Taro Pharmaceuticals Inc.
 ®Tegretol is a registered trademark of Novartis Pharmaceuticals Canada Inc.
 *100 tablet size available soon
 TARO is a registered trademark of Taro Pharmaceuticals Inc.

FROM THE NEWSWIRE

OTTAWA: The Honourable Rona Ambrose, Minister of Health, has announced that the Government of Canada has launched a pilot project targeting patient input from Canadians with rare diseases to help inform future reviews of orphan drugs. As announced in October of 2012, Health Canada has been developing an Orphan Drug Framework to spur innovation and research into new treatments for rare diseases and also to encourage patient participation. The Pilot Project will simulate how input from patients will be gathered and incorporated into the drug submission review process once the Orphan Drug Framework is in effect.

DORVAL, QC: Novartis recently announced that detailed results from two pivotal phase III studies evaluating the interleukin-17A (IL-17A) inhibitor investigational secukinumab (AIN457) were published online in the New England Journal of Medicine (NEJM). Investigational secukinumab met all primary and key secondary endpoints at Week 12. Superiority over placebo in both ERASURE and FIXTURE studies was demonstrated, while FIXTURE study also demonstrated superiority to Enbrel® (etanercept) in improving moderate-to-severe plaque psoriasis symptoms.